Mutant KRAS at the heart of tumor immune evasion
Abstract
In the search for therapeutic combinations for the treatment of cancer, the pairing of targeted inhibitors of oncogenic driver pathways with immunotherapy has largely been overlooked. In Nature, Canon et al. (2019) describe how the novel KRAS-G12C inhibitor AMG 510 can potentiate immune rejection in combination with immune checkpoint blockade.
Full text links
Publisher website (DOI) 10.1016/j.immuni.2019.12.013
Europe PubMed Central 31951548
Pubmed 31951548
Keywords
Related topics
Type of publication
